Dipeptidyl peptidase-4: difference between revisions
Diff·revision 19 → 20·21:07, 14 Jun 2025
Difference between revision 19 and revision 20 of Dipeptidyl peptidase-4. 3 lines changed; the page grew by 446 bytes.
| Revision 19 — 01:24, 19 May 2025 DataTableDunja (talk) add the enteroendocrine cell type responsible for secretion 6,022 bytes ±0 | Revision 20 — 21:07, 14 Jun 2025 EmptyingElke (talk) add the counter-regulatory glucagon point, sourced 6,468 bytes +446 | ||
|---|---|---|---|
| 48 | Because the inhibitors act on endogenous hormone, they are not interchangeable with receptor agonists and combining the two produces little additional benefit — receptor occupancy is already near-maximal under agonist therapy. | 48 | Because the inhibitors act on endogenous hormone, they are not interchangeable with receptor agonists and combining the two produces little additional benefit — receptor occupancy is already near-maximal under agonist therapy. |
| 49 | 49 | ||
| + | 50 | == Analytical relevance == | |
| + | 51 | DPP-4 matters to anyone measuring incretin concentrations. Blood drawn without a DPP-4 inhibitor in the tube continues to degrade GLP-1 ''ex vivo'', and comparisons between studies that did and did not add an inhibitor at collection are not meaningful. Total-GLP-1 assays that detect both intact and truncated forms give systematically higher and less interpretable numbers than intact-specific assays.{{r|holst2007}} | |
| + | 52 | ||
| 50 | == References == | 53 | == References == |
| 51 | {{reflist}} | 54 | {{reflist}} |